february 2011 . food and drug administration: overseas offices have taken steps to help ensure import safety , but more long - term planning is needed . gao - 10-960 . washington , d.c.: september 30 , 2010 . food and drug administration: opportunities exist to better address management challenges . gao - 10-279 . washington , d.c.: february 19 , 2010 . food and drug administration: fda faces challenges meeting its growing medical product responsibilities and should develop complete estimates of its resource needs . gao - 09-581 . washington , d.c.: june 19 , 2009 . medical devices: shortcomings in fda's premarket review , postmarket surveillance , and inspections of device manufacturing establishments . gao - 09-370t . washington , d.c.: june 18 , 2009 . medical devices: fda should take steps to ensure that high - risk device types are approved through the most stringent premarket review process . gao - 09-190 . washington , d.c.: january 15 , 2009 . high - risk series: an update . gao - 09-271 . washington , d.c.: january 2009 . health - care - associated infections in hospitals: number associated with medical devices unknown , but experts report provider practices as a significant factor . gao - 08-1091r . washington , d.c.: september 26 , 2008 . reprocessed single - use medical devices: fda oversight has increased , and available information does not indicate that use presents an elevated health risk . gao - 08-147 . washington , d.c.: january 31 , 2008 . medical devices: challenges for fda in conducting manufacturer inspections . gao - 08-428t . washington , d.c.: january 29 , 2008 . food and drug administration: methodologies for identifying and allocating costs of reviewing medical device applications are consistent with federal cost accounting standards , and staffing levels for reviews have generally increased in recent years . gao - 07-882r . washington , d.c.: june 25 , 2007 . medical devices: status of fda's program for inspections by accredited organizations . gao - 07-157 . washington , d.c.: january 5 , 2007 . this is a work of the u.s. government and is not subject to copyright protection in the united states . the published product may be reproduced and distributed in its entirety without further permission from gao . however , because this work may contain copyrighted images or other material , permission from the copyright holder may be necessary if you wish to reproduce this material separately . the firm said that the rest had likely been used . our preliminary findings also suggest another gap in the recall process â€” insufficient documentation justifying fda's termination decisions . without such documentation , we were unable to assess the extent to which fda's termination process appropriately evaluated recalling firms' corrective actions . although fda requests that firms submit corrective and preventive action plans for review and approval before a recall can be terminated , we found little documentation regarding how fda assessed whether such plans were sufficient when it terminated recalls . when we asked to review documentation justifying the decisions for the 29 terminated recalls in our sample , fda officials indicated that they do not maintain extensive documentation justifying the basis for their termination decisions .